Collecting Data and Blood Samples From Prostate Cancer Patients Receiving Lutetium Treatment
Collects blood samples and treatment data from adults with metastatic prostate cancer receiving Lu-PSMA therapy.
Key facts
- Who runs it
- Erasmus Medical Center
- Where
- Rotterdam, NetherlandsSee the site
- Trial code
- Registry title
- Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics
- Status
- Recruiting
- People taking part
- 150 people, planned
- Started
- 20 Feb 2024
- Expected to end
- 1 Feb 2027
- Type of study
- Observational
- Treatments tested
- Blood draw for ctDNA and circulating tumor cell collection.
- Record updated
- 22 April 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with metastatic prostate cancer who are planned to start Lu-PSMA treatment as part of regular care at the Erasmus MC. Data and blood samples are collected.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Metastatic prostate cancer
Main reasons for not taking part
- Cannot understand the written information
- Cannot give informed consent
- Not planned to start Lu-PSMA treatment as part of regular clinical care
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Participants should be at least 18 years old
- Participants should be able to understand the written information and be able to provide informed consent
- Participants are planned to start treatment with Lu-PSMA as a part of regular clinical care
Who cannot take part
- None applicable
Where in Netherlands
- Erasmus MCRotterdam, NetherlandsContact: Stijn Koolen, PhDTaking people
About the trial
What the trial wants to find out
This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and explore putative biomarkers to identify patients who most benefit from Lu-PSMA treatment.
Treatments tested
- Blood draw for ctDNA and circulating tumor cell collection.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics
- Plain-language title
- Collecting Data and Blood Samples From Prostate Cancer Patients Receiving Lutetium TreatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 22 April 2024